Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SalplusF Inhaler 125/25 fluticasone propionate/salmeterol (as xinafoate) 125 microgram/25 microgram inhalation pressurised aerosol can metered dose, Cipla Australia Pty Ltd, CON-131
Product name
SalplusF Inhaler 125/25 fluticasone propionate/salmeterol (as xinafoate) 125 microgram/25 microgram inhalation pressurised aerosol can metered dose
Sponsor name
Cipla Australia Pty Ltd
Consent start
Consent no.
CON-131
Standard
British Pharmacopoeia monograph for Fluticasone and Salmeterol Pressurised Inhalation, Suspension.
Non-compliance with standard
The products do not comply with the related substances requirements.
Conditions imposed
The expiry limit for the single maximum unknown impurity of fluticasone
proprionate will be NMT 0.3%, and
The expiry limit for the single maximum unknown impurity of salmeterol
will be NMT 0.3%, and
The expiry limit for the total impurities of salmeterol will be NMT 0.8%.
Therapeutic product type
Prescription medicines